Audio Interview

Development of PRO-140 (Leronlimab) as a treatment for COVID-19

Published on April 21, 2020   20 min

Other Talks in the Series: Research and Clinical Interviews

Interviewer: Dr. Jacob Lalezari, thank you very much for taking the time to connect with us today to discuss CytoDyn's efforts in developing a COVID-19 treatment. Your lead molecule right now is a monoclonal antibody called Leronlimab. CytoDyn has been testing Leronlimab in clinical trials for some years now for different indications. What were those indications for Leronlimab and how well did this agent fare in clinical trials? Dr. Lalezari: First of all it's a pleasure to be here today. It's a very curious history with Leronlimab, it has been developed and been in the pipeline for HIV treatment for, I think, about 15 years now, and it's been handed off to one group after another. The mechanism of action is that it is a monoclonal antibody which binds to a T-cell receptor called CCR5, and its activity in HIV is completely separate from our more interesting and recent work in COVID-19. CCR5 is the T-cell receptor that HIV just happens to use to get inside the T-cell. It is there as a receptor that mediates inflammation and cell-trafficking in the immune system, but it just happens to be the receptor that is part of the three-step sequence of HIV entry into T-cells. It has an interesting history because the plague bacillus (called the bubonic plague back in 1347) also used the CCR5 receptor to get inside T-cells,

Development of PRO-140 (Leronlimab) as a treatment for COVID-19

Embed in course/own notes